Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

PURPOSE: KEYNOTE-164 (NCT02460198) evaluated the antitumor activity of pembrolizumab in previously treated, metastatic, microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) colorectal cancer (CRC). METHODS: This phase II open-label study involved 128 centers worldwide. Eligible pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Dung T., Kim, Tae Won, Van Cutsem, Eric, Geva, Ravit, Jäger, Dirk, Hara, Hiroki, Burge, Matthew, O’Neil, Bert, Kavan, Petr, Yoshino, Takayuki, Guimbaud, Rosine, Taniguchi, Hiroya, Elez, Elena, Al-Batran, Salah-Eddin, Boland, Patrick M., Crocenzi, Todd, Atreya, Chloe E., Cui, Yi, Dai, Tong, Marinello, Patricia, Diaz Jr, Luis A., André, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031958/
https://www.ncbi.nlm.nih.gov/pubmed/31725351
http://dx.doi.org/10.1200/JCO.19.02107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031958/
https://www.ncbi.nlm.nih.gov/pubmed/31725351
http://dx.doi.org/10.1200/JCO.19.02107

Ejemplares similares